Last 48 quarters of trend data · Healthcare · Cell & Gene Therapy
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.64 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 0.24 | 1.40 | 0.94 | 0.86 | 0.61 | 1.38 | 1.12 | 0.46 | 0.30 | 0.69 | 0.84 | 0.56 | 0.37 | 0.51 | 0.50 | 0.88 | 0.47 | 0.58 | 0.56 | 0.62 | 0.62 |
| — | +1.3% | -15.8% | +87.1% | +101.7% | +99.6% | +32.5% | -17.1% | -18.5% | +35.3% | +68.4% | -36.7% | -21.5% | -11.5% | -11.2% | +41.9% | -24.0% | -47.0% | -46.8% | -32.1% | -48.3% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -69.9% | -39.2% | -28.5% | -21.9% | -15.8% | -24.0% | -19.5% | -20.9% | -33.6% | -35.0% | -39.4% | -32.3% | -25.4% | -32.5% | -29.6% | -39.7% | -22.4% | -23.4% | -13.9% | -12.8% | -14.6% |
| — | -63.4% | -46.4% | -4.4% | +53.0% | +31.3% | +50.6% | +35.2% | -32.6% | -7.6% | -33.0% | +18.6% | -13.1% | -38.7% | -113.3% | -210.8% | -53.2% | -69.3% | -55.7% | +16.8% | +15.4% | |
| ROA | -63.9% | -32.5% | -26.1% | -20.6% | -14.4% | -21.0% | -17.5% | -18.4% | -28.0% | -27.3% | -30.4% | -26.6% | -20.0% | -25.5% | -23.2% | -32.0% | -19.1% | -19.9% | -12.0% | -11.2% | -13.0% |
| — | -54.8% | -49.0% | -11.6% | +48.7% | +23.2% | +42.4% | +30.6% | -39.8% | -7.2% | -31.2% | +17.0% | -5.0% | -27.9% | -93.6% | -186.5% | -46.9% | -58.5% | -45.9% | +18.7% | +10.3% | |
| ROIC | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — | — | — | — | — | — | 0.00 | 0.01 | 0.01 | 0.02 | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 |
| — | — | — | — | — | — | — | — | — | — | — | — | -71.1% | -35.0% | -23.7% | +38.5% | +16.6% | +20.1% | +12.1% | +11.7% | -72.7% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 49.37 | 12.77 | 15.87 | 66.93 | 49.37 | 22.27 | 9.36 | 10.58 | 5.65 | 6.38 | 3.47 | 5.48 | 5.71 | 4.01 | 5.03 | 3.92 | 6.42 | 7.01 | 6.48 | 8.42 | 8.06 |
| — | -42.7% | +69.5% | +532.6% | +773.6% | +249.1% | +169.5% | +93.0% | -0.9% | +59.1% | -30.9% | +39.7% | -11.1% | -42.8% | -22.4% | -53.4% | -20.4% | -36.3% | -46.4% | -44.6% | +16.7% | |
| Quick Ratio | 49.37 | 12.77 | 15.87 | 66.93 | 49.37 | 22.27 | 9.36 | 10.58 | 5.65 | 6.38 | 3.47 | 5.48 | 5.71 | 4.01 | 5.03 | 3.92 | 6.42 | 7.01 | 6.48 | 8.42 | 8.06 |
| — | -42.7% | +69.5% | +532.6% | +773.6% | +249.1% | +169.5% | +93.0% | -0.9% | +59.1% | -30.9% | +39.7% | -11.1% | -42.8% | -22.4% | -53.4% | -20.4% | -36.3% | -46.4% | -44.6% | +16.7% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -714.20 | -252.10 | -1320.00 | -3450.00 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying PHIO stock.
Phio Pharmaceuticals Corp.'s current P/E is -0.6x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Phio Pharmaceuticals Corp.'s business trajectory between earnings reports.